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Biologically active small molecules have long proven useful in the exploration of cell biology. Although many
early compounds were by-products of drug development efforts, recent increased small molecule screening
efforts in academia have expanded the repertoire of biological processes investigated to include areas of
biology that are not of immediate pharmaceutical interest. Many of these newbioassays score for small mole-
cule–induced phenotypic changes at the cellular or even organismal level and thus have been described as
‘‘chemical genetic’’ screens. However, this analogy with traditional genetic screens is misleading; although
each gene has roughly an equivalent chance of being mutated in a traditional genetic screen, the amount
of ‘‘proteomic space’’ that a chemical genetics approach can reach using current small molecule libraries
is considerably smaller. Thus, new chemical biology methodologies are needed to target the remaining
‘‘undruggable proteome’’ with small druglike molecules.Magic Bullets
Over the last 40 years, the development
of new antiviral, antitumor, antibiotic, and
central nervous system–targeted drugs
has had an immense impact on life expec-
tancy and quality of life (Munos, 2009). In
addition to these direct benefits, drug
development over the past four decades
has indirectly benefited the basic research
community by generating new small
molecule probes for basic biological
studies. As detailed in the other reviews
in this special issue of Chemistry &
Biology, these small molecules have had
a profound impact on many basic biolog-
ical investigations and are among the
impetuses for the burgeoning field of
chemical biology. For example, although
the natural product phosphoinositide
3–kinase (PI3K) inhibitor wortmannin has
played a key role in identifying contribu-
tions for PI3K in biological processes as
diverse as cell survival, histamine release,
glucose uptake, and phagocytosis (Len-
nartz, 1999; Nakanishi et al., 1995; Ui
et al., 1995), this natural product lacks
PI3K isoform specificity. Fortunately,
recent medicinal chemistry efforts have
yielded more isoform-selective inhibitors
that are helping to define PI3K function in
specific cellular contexts (Siragusa et al.,
2010; Soond et al., 2010; Sturgeon et al.,
2008; Wang et al., 2008a). Other examples
of useful biological probes that resultedfrom drug development efforts include
inhibitors for the serine/threonine kinases
MEK, JNK, and GSK-3b (Katsanakis
et al., 2002; Saporito et al., 2002; Takaha-
shi-Yanaga and Sasaguri, 2009; Wang
et al., 2004).
Despite these many successes, there
still are many instances where the right
small molecule probe is lacking. As a
chemical biologist who approaches the
chemistry-biology interface from the bio-
logical side, there have been several occa-
sions when I have wished for a ‘‘magic
bullet’’ to allow for specific regulation of
a biological process of interest. Here, I
discuss the impact of academic screening
efforts on new probe development, the
shortcomings of ‘‘chemical genetic’’ ap-
proaches, and the currently unfulfilled
need for novel libraries of small molecules
capable of controlling intracellular protein
function independently of protein class.
Developing Small Molecule
Biological Probes: Design versus
Serendipity
The availability and diversity of new bioac-
tive probes for research has exploded in
the past two decades, primarily because
of the increase in academic small mole-
cule screening facilities (Wu and Schultz,
2009). Previously, biologically active com-
pounds were either direct by-products of
the pharmaceutical industry’s efforts toChemistry & Biology 17, June 25, 2010develop novel drugs or an indirect conse-
quence of these efforts (e.g., natural
product screens for drug target inhibitors).
Thus, not surprisingly, these early small
molecule probes had biological properties
(e.g., anticancer, antiinflammatory, and
antiangiogenic) that were of interest to
the pharmaceutical industry. Despite their
pharmaceutical origins, many of these
compounds have proven extremely useful
as probes in basic research, such as the
immunosuppressive natural products
FK506 and rapamycin that were instru-
mental in the exploration of immune cell
signaling pathways (Cardenas et al.,
1998). In addition, the use of these probes
in basic research studies has generated
new leads for novel drug targets, thus
generating renewed interest in their thera-
peutic potential. For example, the identifi-
cation of methionine aminopeptidase–2
(METAP2) as the target of the antiangio-
genic microbial metabolite fumagillin has
led to the development of novel antiangio-
genic METAP2 inhibitors (Kallander
et al., 2005; Marino et al., 2007; Sin et al.,
1997; Wang et al., 2008b). These early
probes, however useful, failed to span
the breadth of cell biology, thus leaving
many areas that lacked small molecule-
based research tools.
Although small molecule–powered cell
biology research proved very successful,
such as in the use of novel histoneª2010 Elsevier Ltd All rights reserved 551
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of chromatin structure in gene regulation
(Yoshida et al., 2001), most of the early
chemical biology probes were limited to
those research areas of interest to the
pharmaceutical industry. However, once
academic laboratories began to acquire
small molecule screening capabilities,
new compounds could be identified pos-
sessing biological activities unrelated to
drug development. This second genera-
tion of small molecule probe development
relies more on targeted screens looking
for compounds with highly specific bio-
logical activities, as opposed to more
general phenotypes such as decreased
proliferation (Kawasumi and Nghiem,
2007; Schlueter and Peterson, 2009).
Moreover, it has allowed for increased
input from the basic biology research
community to custom design and select
compounds with particular biological
characteristics. For example, a high-
content cell-based assay for perturbation
of mitotic spindle formation yielded mon-
astrol, an inhibitor of the kinesin KIF11
(Mayer et al., 1999). Subsequent studies
using monastrol demonstrated the impor-
tance of KIF11 in normal spindle body
formation (Kapoor et al., 2000; Kapoor
and Mitchison, 2001). Blebbistatin is
another small molecule probe that re-
sulted from a basic biology-driven screen.
Identified as a nonmuscle myosin II inhib-
itor, blebbistatin has been critical in the
investigation of cleavage furrow formation
during mitosis and cytokinetic contractile
ring assembly (Straight et al., 2003). Like-
wise, new assays have been developed to
screen for inhibitors of the Wnt/b-catenin
pathway, which is a major developmental
biology signaling pathway. In a creative
fusion of a small molecule and RNA inter-
ference (RNAi) screening, the Moon labo-
ratory recently identified Bruton’s tyrosine
kinase (BTK) as a Wnt/b-catenin pathway
inhibitor (James et al., 2009). These
targeted proactive approaches to small
molecule probe identification contrast
with the more serendipitous nature of
how traditional chemical biology probes
were discovered and continues to have
a major impact on biology through the
identification of useful research reagents.
Chemical Genetics: An Unrealized
Dream
This growth in novel bioassays has gener-
ated many new research tools, as well as552 Chemistry & Biology 17, June 25, 2010 ªexcitement about the potential for small
molecule–based biological discovery, in
general. Indeed, the use of a combination
of new bioassay development and com-
pound library screening to identify novel
bioactive molecules has become com-
monplace on campuses today (Sachinidis
et al., 2008; Soderholm et al., 2006;
Specht and Shokat, 2002; Wheeler and
Brandli, 2009). Many of these new screens
are phenotype-based—that is, assays
that screen for small molecule–induced
changes in a cellular context or even in
whole organisms such as zebrafish,
Drosophila, or nematodes. Because these
screens score for a change in phenotype
without regard a priori to a given target
protein, this approach has been com-
pared to a traditional ‘‘forward’’ genetic
screen, leading to the sobriquet ‘‘chemical
genetics’’ to describe these small
molecule screens. However semantically
appealing this analogy with traditional
genetic screening may be, it is grossly
misleading; although each gene has an
equivalent chance of being mutated in
a traditional genetic screen (ignoring
mutagenic hotspots for the sake of argu-
ment), the amount of ‘‘proteomic space’’
that a chemical genetics approach can
reach using small molecule perturbagens
is considerably smaller. Put another way,
the oft-stated goal of ‘‘a small molecule
inhibitor for every protein’’ has yet to be
realized.
Today’s Challenge: Targeting
the Undruggable Proteome
Both academic and pharmaceutical
screening efforts have been inherently
limited in the types of proteins that are tar-
geted using small molecules—that is, the
segment of proteome that is character-
ized by the presence of well-defined small
molecule binding pockets, such as ion
channels, nuclear receptors, GPCRs, or
enzymes (Overington et al., 2006). Collec-
tively, these protein families are but a frac-
tion of the entire proteome and, thus, this
exclusive focus leaves as ‘‘undruggable’’
many other types of proteins that cannot
be controlled using small molecules,
such as transcription factors, nonenzy-
matic proteins, regulatory or scaffolding
proteins, and so forth. (Arakaki et al.,
2006; Verdine and Walensky, 2007). The
challenge, therefore, is how can one
develop a methodology that targets this
undruggable proteome? Is it possible to2010 Elsevier Ltd All rights reservedmake every protein equally susceptible
to small molecule control? I argue that
a true chemical genetic screen will require
a small molecule library that targets both
traditional drug targets as well as the
80% of the proteome lacking a catalytic
site or a small molecule binding site that
controls protein function when occupied.
Wanted: Controlling Protein
Function Irrespective of Protein
Class
Given the incomplete coverage of the pro-
teome by current compound libraries, new
methods are needed to control protein
function using small molecules. One
possible solution is to use the cell’s own
quality control mechanisms to induce the
degradation of targeted proteins and
thus modulate intracellular protein con-
centrations. For example, a recent report
described the use of heat shock cognate
protein HSC70 peptide-binding motifs to
recruit proteins to the lysosome for degra-
dation (Figure 1A) (Bauer et al., 2010). By
harnessing HSC70, a chaperonin protein
responsible for either the refolding or tar-
geted degradation of misfolded proteins,
this approach selectively induced the
degradation of mutant huntingtin, the pro-
tein responsible for Huntington’s disease
and, moreover, ameliorated disease in an
animal model.
A similar approach to use cellular
protein degradation machinery to control
intracellular protein levels was developed
in my laboratory, in collaboration with
Ray Deshaies (CalTech). Although the
approach described above recruits tar-
geted proteins to the lysosome for degra-
dation, Proteolysis Targeting Chimeras
(PROTACs) recruit targeted proteins to
E3 ubiquitin ligases (Rodriguez-Gonzalez
et al., 2008; Schneekloth and Crews,
2005) as a first step in their induced degra-
dation. E3 ubiquitin ligases, together
with E2-conjugating enzymes, are re-
sponsible for coupling the 76 amino acid
tag ubiquitin to lysine 3-amino groups on
the surface of proteins, thus targeting
them for degradation by the major intra-
cellular proteolytic complex, the 26S
proteasome. As heterobifunctional com-
pounds composed of a target protein-
binding ligand and an E3 ubiquitin ligase
ligand (Figure 1), PROTACs induce
proteasome-mediated degradation of
selected proteins via their recruitment to
E3 ubiquitin ligase and subsequent
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Figure 1. Strategies for Using Cellular Protein Degradation
Machinery to Control Intracellular Protein Levels
(A) Schematic of inducing protein degradation via recruitment to the protea-
some or lysosome.
(B) Design of a PROTAC-based library targeting protein function indepen-
dently of protein class.
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han et al., 2005). In several
proof-of-concept studies, this
method has been shown to
induce intracellular protein
degradation with greater tem-
poral and dosage control than
that offered by RNAi-medi-
ated gene knockdown (Pup-
pala et al., 2008; Sakamoto
et al., 2003; Schneekloth
et al., 2004). In addition, unlike
the lysosomal targeting ap-
proach using peptidic HSC70
binding motifs, it is possible
to target proteins for deg-
radation using a nonpepti-
dic, all-small-molecule–based
PROTAC (Itoh et al., 2010;
Schneekloth et al., 2008).
Affinity-Based HTS
screens: An Unbiased
Approach to Identify
a Ligand for Every
Protein
Whether targeting proteins for
proteasomal- or lysosomal-
mediated degradation, theseapproaches for controlling intracellular
protein levels face the same major chal-
lenge, namely, the identification of ligands
for proteins to be targeted for degrada-
tion. Fortunately, new advances in high-
throughput affinity-based screening are
helping to address this challenge (Zhu
and Cuozzo, 2009). Unlike common func-
tional assay–based HTS, which identifies
compounds according to their ability to
elicit a biological consequence upon
binding, affinity-based HTS instead
focuses only on identifying compounds
that bind their protein targets, irrespective
of their protein class. Although several
low- and medium-throughput affinity
strategies are available (e.g., calorim-
etry-based, surface plasmon resonance–
based, NMR/X-ray structure-based,
mass spectrometry-based, small mole-
cule microarrays), newer methods offer
the ability to screen readily hundreds of
thousands to millions of compounds
(Zhu and Cuozzo, 2009). For example,
several related DNA-tagged small mole-
cule libraries (Gartner et al., 2004; Melkko
et al., 2007) have been used to identify
protein ligands from libraries as large as
108 compounds (Clark et al., 2009). As
these technologies continue to mature,low- and medium-throughput affinity-
based approaches should become more
amenable to HTS. Hence, functionally
unbiased affinity-based HTS screens
hold the promise of identifying a ligand
to each protein in the proteome. Although
ligands identified for each protein by
these methods may not have an inherent
biological activity, when they are coupled
to an approach such as PROTACs, they
will ultimately allow for the elusive all-en-
compassing chemical genetic screen.
The Molecules of My Dreams:
A Truly Comprehensive Small
Molecule Library
In theory, coupling protein ligands identi-
fied in affinity-based screens to an
HSC70 ligand or an E3 ligase ligand
(e.g., the MDM2-binding compound nut-
lin) would generate compounds capable
of targeting any desired protein for intra-
cellular degradation (Schneekloth et al.,
2008). Although all of the technology
is in place to generate a degradation-
inducing compound for every protein, I
question whether this ‘‘reverse’’ genetic
approach is the best. Instead of starting
with individual proteins and identifying
novel targeting ligands to them for incor-Chemistry & Biology 17, June 25, 2010 ª2010 Elseporation into such molecules,
why not take a forward
genetic approach to score
a cellular phenotype on the
basis of loss of protein func-
tion? A library of PROTACs
could be generated in which
all compounds possess the
same E3 ubiquitin ligase
ligand, but each is coupled
to a different chemical diver-
sity element (Figure 1B).
Such a naive PROTAC library
of sufficient size might be
capable of binding to (and
inducing the degradation of)
every protein within the pro-
teome irrespective of protein
function or class. However,
there are several limitations
to this strategy. First, some
proteins are naturally unsta-
ble and, thus, would be diffi-
cult to control via a PROTAC.
Likewise, it may be difficult to
find a small molecule ligand
capable of binding to a target
protein with the requisite
affinity and specificity for usein a PROTAC. Despite these potential
limitations, the generation of a PROTAC-
based compound collection would repre-
sent the first step toward a comprehensive
small molecule library that could be used
to perform proteomewide chemical ge-
netic screens for induction or modulation
of a given cellular phenotype.
The development of new research
strategies has permitted small molecule
bioassays and screens to evolve signifi-
cantly in the past two decades. This has
enabled researchers to investigate more
basic biological phenomena beyond
those areas mandated by clinical needs.
Nevertheless, much remains to be done
before the dream of a small molecule
perturbagen for every protein is realized.
In my opinion, the largest unmet need
in bioprobe development today is the
ability to modulate protein function inde-
pendently of protein class. Although
several current technologies offer possi-
ble solutions to this challenge, chemical
genetics will not truly be on par with
traditional genetics until this challenge is
overcome.
Chemistry & Biology invites your
comments on this topic. Please write
to the editors at chembiol@cell.com.vier Ltd All rights reserved 553
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